C. Ola Landgren, Leader of Translational and Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared a post on LinkedIn:
“The FDA has approved subcutaneous (SC) Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens for the treatment of patients with multiple myeloma across all existing indications of Sarclisa intravenous (IV) formulation.
With the approval, Sarclisa Escena is the first anticancer treatment to be administered through both an on-body injector and manual SC administration.”
Other articles about FDA on OncoDaily.